GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Natco Pharma NATCOPHARM.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

804.35

-0.33%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

16 analysts, 1 Feb 2026. The analysts' own views, not ours.

  • 2Strong buy
  • 1Buy
  • 4Hold
  • 5Sell
  • 4Strong sell

Price targets

Brokers' own targets, 1 Feb 2026. Not our view.

Last close 804.35Average target 924.22

Low
719.12
Average
924.22
Median
930.75
High
1,260.00

Forecasts

Analyst averages for the fiscal years ahead

FY2027FY2028FY2029
Revenue₹32.40bn₹36.53bn₹43.35bn
Revenue, highest₹34.91bn₹39.92bn₹46.44bn
Revenue, lowest₹28.43bn₹28.41bn₹41.02bn
Earnings per share42.9450.0461.37
Earnings per share, highest45.4457.0564.20
Earnings per share, lowest40.5633.0755.70
Analysts793

Earnings against forecasts

Earnings per share by fiscal quarter

Q1 2026Q4 2025Q3 2026Q3 2025Q2 2026Q2 2025Q1 2024Q4 2024
Forecast15.765.271.2224.5025.1932.1316.0116.33
Reported11.758.438.4628.9428.9437.8121.5621.56
Difference-25.4%+60.0%+591.2%+18.1%+14.9%+17.7%+34.7%+32.0%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

8 / 10

Revenue growth 14.6% a year over 10 years. Return on equity 15.4%.

Model fair value

978.86

From earnings 978.86, from revenue 1,018.53.

Piotroski score

3 / 9

A nine-point test of financial strength, for 31 Mar 2026.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.